Management of sickle cell disease: Recent advances and controversies

British Journal of Haematology

Volumn 107, Issue 1, 1999, Pages 2-11

  Castro, Oswaldo ^a,b  

^a HOWARD UNIVERSITY   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

Bacterial infection; Bone marrow transplantation; Cerebrovascular occlusion; Sickle cell disease; Vaso occlusive events

Indexed keywords

HYDROXYUREA; PENICILLIN DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; BLOOD TRANSFUSION; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; DOSE RESPONSE; HUMAN; INFECTION PREVENTION; LASER COAGULATION; LEUKEMIA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SICKLE CELL ANEMIA; STREPTOCOCCUS INFECTION; STROKE; TREATMENT PLANNING;

ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYUREA; LASER COAGULATION;

EID: 0032710432     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01565.x     Document Type: Review

References (108)

1. Adams, J.G., III (1994) Clinical laboratory diagnosis. Sickle Cell Disease: Basic Principles and Clinical Practice (ed. by S.H. Embury, R.P. Hebbel, N. Mohandas and M.H. Steinberg). pp. 457-468. Raven Press, New York.
2. Adams, R.J., McKie V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F.T., Bonds, D.R. & Brambilla, D. (1998) Prevention of a first stroke by transfusion in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine, 339, 5-11.
3. Adams, R.J., McKie, V., Nichols, F., Carl, E., Zhang, D.L., McKie, K., Figueroa, R., Litaker, M., Thompson, W. & Hess, D. (1992) The use of transcranial ultrasonography to predict stroke in sickle cell disease. New England Journal of Medicine, 326, 605-610.
4. S haplotypes and α- and β-thalassemia alleles in the Arabian peninsula. Hemoglobin, 21, 281-296.
5. Ambruso, D.R., Githens, J.H., Alcorn, R., Dixon, D.J., Brown, L.J., Vaughn, W.M. & Hays, T. (1987) Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion, 27, 94-98.
6. Anderson, R.R., Sosler, S.D., Kovach, J. & DeChristopher, P.J. (1997) Delayed hemolytic transfusion reaction due to anti-Jsa in an alloimmunized patient with a sickle cell syndrome. Transfusion, 108, 658-661.
7. Balkaran, B., Char, G., Morris, J.S., Thomas, P.W., Serjeant, B.E. & Serjeant, G.R. (1992) Stroke in a cohort of patients with homozygous sickle cell disease. Journal of Pediatrics, 120, 360-366.
8. Ballas, S.K. (1997) Management of sickle pain. Current Opinion in Hematology, 4, 104-111.
9. Ballas, S.K., Marcolina, M.J., Dover, G.J., Barton, F.B., and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (1999) Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. British Journal of Haematology 105, 491-496.
10. Berk, P.D., Wasserman, L.R., Fruchtman, S.M. & Goldberg, J.D. (1995) Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. Polycythemia Vera and the Myeloproliferative Disorders (ed. by L. R. Wasserman, P. D. Berk and N. I. Berlin). pp. 166-194. Saunders, Philadelphia.
11. Berkovitch, M., Papadouris, D., Shaw, D., Onuaha, N., Dias, C. & Olivieri, N.F. (1998) Trying to improve compliance with prophylactic peniclllin therapy in sickle cell disease. British Journal of Clinical Pharmacology, 45, 605-607.
12. Bernaudin, F., Souillet, G., Vannier, J.P., Plouvier, E., Lemerle, S., Michel, G., Bordigoni, P., Lutz, P. & Kuentz, M. (1993) Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO. Bone Marrow Transplantation, 12, (Suppl. 1), 118-121.
13. Best, P.J., Daoud, M.S., Pittelkov, M.R. & Petit, R.M. (1998) Hydroxyurea-induced leg ulceration in 14 patients. Annals of Internal Medicine, 128, 29-32.
14. Bristol-Myers Squibb Company (1998) Droxia™ (hydroxyurea capsules, USP). American Hospital Formulary Service Product Information Form.
15. Castro, O., Brambilla, D.J., Thorington, B., Reindorf, C.A., Scott, R.B., Gillette, P., Vera, J.C. & Levy, P.S. (1994) The acute chest syndrome in sickle cell disease: incidence and risk factors. New England Journal of Medicine, 84, 643-649.
16. Castro, O. & Sandler, S.G. (1995) Estimating the effect of donor-recipient phenotype matching for transfusions in sickle cell patients. (Abstract). Blood, 86, (Suppl. 1), 644a.
17. Charache, S., Barton, F.B., Moore, R.D., Terrin, M.L., Steinberg, M.H., Dover, G.J., Ballas, S.K., McMahon, R.P., Castro, O., Orringer, E.P. and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (1996) Hydroxyurea in sickle cell anemia: clinical utility of a myclosuppressive 'switching' agent. Medicine, 75, 300-326.
18. Charache, S., Dover, G.J., Moore, R.D., Eckert, S., Ballas, S.K., Koshy, M., Milner, P.F., Orringer, E.P., Phillips, G., Jr, Platt, O.S. & Thomas, G.H. (1992) Hydroxyurea: effects on Hb F production in patients with sickle cell anemia. Blood, 79, 2555-2565.
19. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P., Bonds, D.R., and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine, 332, 1317-1322.
20. Cohen, A.R. (1998) Sickle cell disease: new treatments, new questions. New England Journal of Medicine, 339, 42-44.
21. Collins, A.F., Fassos, F.F., Stobie, S., Lewis, N., Shaw, D., Fry, M., Templeton, D.M., McClelland, R.A., Koren, G. & Olivieri, N.F. (1994) Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4one (LJ) in iron-loaded patients with sickle cell disease. Blood, 83, 2329-2333.
22. Davies, S.C. & Olatunji, P.O. (1995) Blood transfusion in sickle cell disease. Vox Sanguinis, 68, 145-151.
23. Deeg, H.J., Leisering, W., Storb, R., Nims, J., Flowers, M.E.D., Witherspoon, R.P., Sanders, J. & Sullivan, K.M. (1998) Long-term outcome after marrow transplantation for severe aplastic anemia. Blood, 91, 3637-3645.
24. DePass, L.R. & Weaver, E.V (1982) Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains. Journal of Toxicology and Environmental Health 10, 297-305.
25. DeSimone, J., Heller, P., Hall, I. & Zwiers, D. (1982) 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proceedings of the National Academy of Sciences of the United States of America, 79, 4428-4431.
26. Falletta, J.M., Woods, G.M., Verter, J.I., Buchanan, G.R., Pegelow, C.H., Iyer, R.V., Miller, S.T., Holbrook, C.T., Kinney, T.R., Vichinsky, E., Becton, D.L., Wang, W., Johnstone, H.S., Wethers, D.L., Reaman, G.H., DeBaum, M.R., Grossman, N.J., Kallnyak, K., Jorgensen, J.H., Bjornson, A., Thomas, M.D. & Reid, C., for the Prophylactic Penicillin Study II (1995) Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. Journal of Pediatrics, 127, 685-690.
27. Farber, M.D., Jampol, L.M., Fox, P., Moriarty, B.J., Acheson, R.W., Rabb, M.F. & Serjeant, G.R. (1991) A randomized clinical trial of scatter photocoagulation of proliferative sickle retinopathy. Archives of Ophthalmology. 109, 363-367.
28. Ferster, A., Corazza, F., Vertongen, F., Bujan, W., Devalck, C., Fondu, P., Cochaux, P., Lambermont, M., Khaladji, Z. & Sariban, E. (1995) Transplanted sickle-cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity. British Journal of Haematology. 90, 804-808.
29. Ferster, A., Vermyelen, C., Cornu, G., Buyse, M., Corazza, F., Devalck, C., Fondu, P., Toppet, M. & Sariban, E. (1996) Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood, 88, 1960-1964.
30. Fink, L. & Collins, F.S. (1997) The Human Genome Project: view from the National Institutes of Health. Journal of the American Medical Womens Association, 52, 4-7.
31. Fruchtman, S.M., Macke, K., Kaplan, M.E., Peterson, P., Berk, P.D. & Wasserman, L.R. (1997) From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Seminars in Hematology. 34, 17-23.
32. Gaston, M.H., Verter, J.I., Woods, G., Pegelow, C., Kelleher, J., Presbury, G., Zarkowsky, H., Vichinsky, E., Iyer, R., Lobel, J.S., Diamond, S., Holbrook, T., Gill, F.M., Ritchey, K. & Falletta, J.M., for the Prophylactic Penicillin Group (1986) Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. New England Journal of Medicine, 314, 1593-1599.
33. Gimmon, Z., Wexler, M.R. & Rachmilewitz, E.A. (1982) Juvenile leg ulceration in beta-thalassemia major and intermedia. Plastic and Reconstructive Surgery 69, 320-325.
34. el-Hazmi, M.A. (1991) Heterogeneity and variation of clinical and haematological expression of haemoglobin S in Saudi Arabs. Acta Haematologica, 88, 67-71.
35. Herrick, J.B. (1910) Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Archives of Internal Medicine, 6, 517-521.
36. Hilliard, L.M., Williams, B.F., Lounsbury, A.E. & Howard, T.H. (1998) Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. American Journal of Hematology, 59, 28-35.
37. Hoelzer, G.A., Wallman, J. & Melnick, D.J. (1998) The effects of social structure, geographical structure, and population size on the evolution of mitochondrial DNA. II. Molecular clocks and the lineage sorting period. Journal of Molecular Evolution, 47, 21-31.
38. Jacobson, M.S., Gagliano, D.A., Cohen, S.B., Rabb, M.F., Jampol, L.M., Farber, M.D. & Goldberg, M.F. (1991) A randomized clinical trial of feeder vessel photocoagulation of sickle cell retinopathy: a long-term follow-up. Ophthalmology, 98, 581-585.
39. Jiang, J., Jordan, S.J., Barr, D.P., Gunther, M.R., Maeda, H. & Mason, R.P. (1997) In vivo production of nitric oxide in rats after administration of hydroxyurea. Molecular Pharmacology 52, 1081-1086.
40. Johnson, F.L., Look, A.T., Cockerman, J., Ruggiero, M.R., Dalla-Pozza, L. & Billings, F.T., III (1984) Bone marrow transplantation in a patient with sickle cell anemia. New England Journal of Medicine, 311, 780-783.
41. Kaplan, S.L., Mason, E.O., Jr, Barson, W.J., Wald, E.R., Arditi, M., Tan, T.Q., Schutze, G.E., Bradley, J.S., Givner, L.B., Kim, K.S. & Yogev, R. (1998) Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics, 102, 538-545.
42. Konotey-Ahulu, F.I.D. (1991) The Sickle Cell Disease Patient. McMillan, London.
43. Koshy, M., Burd, L., Wallace, D., Moawad, A. & Baron, J. (1988) Prophylactic red-cell transfusions in pregnant patients with sickle cell disease: a randomized cooperative study. New England Journal of Medicine, 319, 1447-1452.
44. Kumar, S. & Hedges, S.B. (1998) A molecular timescale for vertebrate evolution. Nature, 392, 917-920.
45. Lawrence, P., Aronson, I., Saxe, N. & Jacobs, P. (1991) Leg ulcers in hereditary spherocytosis. Clinical and Experimental Dermatology. 16, 28-30.
46. Leitman, S.F., Hill, E.A., Moore, R.C. & Klein, H.G. (1991) Efficacy of erythrocytapheresis in the treatment of sickle cell disease. (Abstract). Blood, 78, (Suppl. 1), 199a.
47. Lessin, L.S., Kurantsin-Mills, J., Klug, P.P. & Weems, H.B. (1978) Determination of rheologically optimal mixtures of AA and SS erythrocytes for transfusion. Progress in Clinical and Biological Research, 20, 124-134.
48. Liakopoulou, E., Blau, C.A., Li, Q., Josephson, B., Wolf, J.A., Fournarakis, B., Raisys, V., Dover, G., Papayannopoulou, T. & Stamatoyannopoulos, G, (1995) Stimulation of fetal hemoglobin production by short chain fatty acids. Blood, 86, 3227-3236.
49. Lima, C.S., Arruda, V.R., Costa, F.F. & Saad, S.T. (1997) Minimal doses of hydroxyurea for sickle cell disease. Brazilian Journal of Medical Biological Research, 30, 993-940.
50. Lutty, G.A. & Goldberg, M.F. (1994) Ophthalmologic complications. Sickle Cell Disease: Basic Principles and Clinical Practice (ed. By S. H. Embury, R. P. Hebbel, N. Mohandas and M. H. Steinberg). pp. 703-724. Raven Press, New York.
51. Mallory, D., Malamut, D. & Sandler, S.G. (1992) A decade of rare donor services in the United States. Report of the American Red Cross Rare Donor Registry (1981-1990). Vox Sanguinis, 63, 186-191.
52. McIntosh, S., Rooks, Y., Ritchey, A.K. & Pearson, H.A. (1980) Fever in young children with sickle cell disease. Journal of Pediatrics, 96, 199-204.
53. Meier-Redelsperger, M., de Montalembert, M., Flahault, A., Neonato, M.G., Ducrocq, R., Masson, M.P., Girot, R. & Elion, J. (1998) Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood, 91, 4472-4479.
54. Miller, D.M., Winslow, R.M., Klein, H.G., Wilson, K.C., Brown, F.L. & Stathan, N.J. (1980) Improved exercise performance after exchange transfusion in subjects with sickle cell anemia. Blood, 56, 1127-1131.
55. Miniero, R., Rocha, V., Saracco, P., Locatelli, F., Brichard, B., Nagler, A., Roberts, I., Yaniv, I., Beksae, M., Bernaudin, E. & Gluckman, E. (1998) Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord. Bone Marrow Transplant, 22, (Suppl. 1), S78-S78.
56. Mukherjee, M.B., Surve, R., Tamankar, A., Gangakhedhar, G.G., Ghosh, K., Lu, C.Y., Krishnamoorthy, R., Colah, R. & Mohanty, D. (1998) The influence of α-thalassemia on the haematological and clinical expression of sickle cell disease in Western India. Indian Journal of Medical Research, 107, 178-181.
57. Nagel, R.L., Bookchin, R.M., Johnson, J., Labie, D., Wajeman, H., Isaac-Sodeye, WA., Honig, G.R., Schillro, G., Crookston, J.H. & Matsutomo, K. (1979) Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proceedings of the National Academy of Sciences of the United States of America, 76, 670-672.
58. Ness, P.M. (1994) To match or not to match: the question for chronically transfused patients with sickle cell anemia. Transfusion, 34, 558-560.
59. Neumayr, L., Koshy, M., Haberkern, C., Earles, A.N., Bellevue, R., Hassell, K., Miller, S., Black, D., Vichinsky, E., and the Preoperative Transfusion in Sickle Cell Disease Study Group (1998) Surgery in patients with hemoglobin SC disease. American Journal of Hematology. 57, 101-108.
60. Ohene-Frempong, K. & Smith-Whitley, K. (1997) Use of hydroxyurea in children with sickle cell disease: what comes next? Seminars in Hematology. 34, (Suppl. 3), 30-41.
61. Ohene-Frempong, K., Weiner, S.J., Sleeper, L.A., Miller, S.T., Embury, S., Moohr, J.W., Wethers, D.L., Pegelow, C.H., Gill, F.M., and the Cooperative Study of Sickle Cell Disease (1998) Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood, 91, 288-294.
62. Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D. & Fleming, K.A. (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine, 339, 417-423.
63. Orringer, E.P., Fowler, V.G., Teague, M.J., Johnson, A.F., Coffey, B., Phillips, G. & Parker, J.C. (1992) Sickle cell leg ulcers: a possible role for hydroxyurea therapy. (Abstract). Clinical Research, 40, 377a.
64. Pearson, H.A., Cornelius, E.A., Schwartz, A.D., Zelson, J.H., Wolfson, S.L. & Spencer, R.P. (1970) Transfusion reversible asplenia in young children with sickle-cell anemia. New England Journal of Medicine, 283, 334-337.
65. Pegelow, C.H., Adams, R.J., McKie, V., Abboud, M., Berman, B., Miller, S.T., Olivieri, N., Vichinsky, E., Wang, W. & Brambilla, D. (1995) Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 126, 896-899.
66. Perrine, R.P., Pembrey, M.E., John, P., Perrine, S. & Shoup, F. (1978) Natural history of sickle cell anemia in Saudi Arabs: a study of 270 subjects. Annals of Internal Medicine, 88, 1-6.
67. Perrine, S.P., Olivieri, N.F., Faller, D.V., Vichinsky, E.P., Dover, G.J. & Ginder, G.D. (1994) Butyrate derivatives: new agents for stimulating fetal globin production in beta-globin disorders. American Journal of Pediatric Hematology and Oncology 15, 67-71.
68. Piomelli, S. (1991) Sickle cell diseases in the 1990's: the need for active and preventive intervention. Seminars in Hematology, 28, 227-232.
69. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease: life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639-1644.
70. Platt, O.S., Thorington, B.D., Brambilla, D.J., Milner, P.F., Rosse, W.F., Vichinsky, E. & Kinney, T.R. (1991) Pain in sickle cell disease: rates and risk factors. New England Journal of Medicine, 325, 11-16.
71. Powars, D., Adams, R.J., Nichols, F.T., Milner, P., Charache, S. & Sarniak, S. (1990) Delayed intracranial hemorrhage following cerebral infarction in sickle cell anemia. Journal of the Association for Academic Minority Physicians, 1, 79-82.
72. Powars, D.L., Sandhu, M., Niland-Weiss, J., Johnson, C., Bruce, S. & Manning, P.R. (1986) Pregnancy in sickle cell disease. Obstetrics and Gynecology, 67, 217-228.
73. Ramsey, G. & Smietana, S.J. (1995) Multiple or uncommon red cell alloantibodies in women: association with autoimmune disease. Transfusion, 35, 582-586.
74. Rana, S., Houston, P.E., Surana, N., Shalaby-Rana, E.I., & Castro, O.L. (1997) Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke. Journal of Pediatrics, 131, 757-760.
75. Ranney, H.M. (1994) Historical milestones. Sickle Cell Disease: Basic Principles and Clinical Practice, (ed. by S. H. Embury, R. P. Hebbel, N. Mohandas and M. H. Steinberg), pp. 1-5. Raven Press New York.
76. Raven Press, New York. Rogers, D.W., Clarke, J.M., Cupidore, L., Ramlal, A.M., Sparke, B.R. & Serjeant, G.R. (1978) Early deaths in Jamaican children with sickle cell disease. British Medical Journal, i, 1515-1516.
77. Rosse, W.F., Gallagher, D., Kinney, T.R., Castro, O., Dosik, H., Moohr, J., Wang, W. & Levy, P.S. (1990) Transfusion and alloimmunization in sickle cell disease. Blood, 76, 1431-1437.
78. Russell, M.O., Goldberg, H.J., Hudson, A., Kim, H.C., Halus, J., Reivich, M. & Schwartz, E. (1984) Effect of transfusion therapy on arteriographic abnormalities and on the recurrence of stroke in sickle cell disease. Blood, 63, 162-169.
79. Sandler, S.G., Mallory, D., Wolfe, J.S., Byrne, P. & Lucas, D.M. (1997) Screening with monoclonal anti-Fy3 to provide blood for phenotype-matched transfusions for patients with sickle cell disease. Transfusion, 37, 393-397.
80. Schroeder, W.A., Munger, E.S. & Powars, D.R. (1990) Sickle cell anaemia, genetic variations and the slave trade to thee United States. Journal of African History, 31, 163-180.
81. Scott, J.P., Hillery, C.A., Brown, E.R., Misiewicz, V. & Labotka, R.J. (1996) Hydroxyurea therapy in children severely affected with sickle cell disease. Journal of Pediatrics, 128, 820-828.
82. Selby, R., Nisbet-Brown, E., Basram, R.K., Chang, L. & Olivieri, N.F. (1997) Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. (Letter). Blood, 90, 891-893.
83. Serjeant, G.R. (1985) Sickle Cell Disease. Oxford University Press, New York.
84. Serjeant, G.R. (1996) The role of preventive medicine in sickle cell disease. The Watson Smith lecture. Journal of the Royal College of Physicians, London, 30, 37-41.
85. Smith, J.A. & Wethers, D.L. (1994) Health care maintenance. Sickle Cell Disease: Basic Principles and Clinical Practice (ed. by S. H. Embury, R. P. Hebbel, N. Mohandas und M. H. Steinberg). pp. 739-744. Raven Press, New York.
86. Spanos, T., Karageorga, M., Ladis, V., Peristeri, J., Hatziliami, A. & Kattamis, C. (1990) Red cell alloantibodies in patients with thalassemia. Vox Sanguinis, 58, 50-55.
87. Statius van Eps, L.W., Schouten, H., Ter Haar Romeny-Wachter, C.H. & La Porte-Wysman, L.W. (1970) The relation between age and urine concentrating capacity in sickle cell disease and hemoglobin C disease. Clinica Chimica Acta, 27, 501-511.
88. Steinberg, M.H., Lu, Z.H., Barton, F.B., Terrin, M.L., Charache, S. & Dover, G.L. (1997a) Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood, 89, 1078-1088.
89. Steinberg, M.H., Nagel, R.L. & Brugnara, C. (1997b) Cellular effects of hydroxyurea in Hb SC disease. British Journal of Haematology, 98, 838-844.
90. Styles, L.A., Lubin, B., Vichinsky, E., Lawrence, S., Hua, M., Test, S. & Kuypers, F. (1997) Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood, 89, 2254-2259.
91. Tahhan, H.R., Holbrook, C.T., Brady, L.R., Brewer, L.D. & Christie, J.D. (1994) Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion, 34, 562-569.
92. Vermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhonge, C., Benoit, Y., Beguin, Y., Dresse, M.F. & Sariban, E. (1998) Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplantation, 22, 1-6.
93. Vermylen, C., Fernandez-Robles, E., Ninane, J. & Cornu, G. (1988) Bone marrow transplantation in five children with sickle cell anaemia. Lancet, i, 1427-1428.
94. Vichinsky, E.P., (1997) Hydroxyurea in children: present and future. Seminars in Hematology, 34, (Suppl. 3), 22-29.
95. Vichinsky, E.P., Earles, A., Johnson, R.A., Hoag, S., Williams, A. & Lubin, B. (1990) Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. New England Journal of Medicine, 322, 1617-1621.
96. Vichinsky, E.P., Haberkern, C.M., Neumayr, L., Earles, A.N., Black, D., Koshy, M., Pegelow, C., Abboud, M., Ohene-Frempong, K. & Iyer, R.V. (1995) A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. New England Journal of Medicine, 333, 206-213.
97. Vichinsky, E.P. & Lubin, B.H. (1994) A cautionary note regarding hydroxyurea in sickle cell disease. Blood. 83, 1124-1128.
98. Voskaridou, E., Kalotychou, V. & Loukopoulos, D. (1995) Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia. British Journal of Haematology, 89, 479-484.
99. Walters, M.C., Patience, M., Leisenring, W., Eckman, J.R., Buchanan, G.R., Rogers, Z.R., Olivieri, N.E., Vichinsky, E., Davies, S.C., Mentzer, W.C., Powars, D., Scott, J.P., Bernaudin, F., Ohene-Frempong, K., Darbyshire, P.J., Wayne, A., Roberts, I.A., Dinndorf, P., Brandalise, S., Sanders, J.E., Matthews, D.C., Appelbaum, F.R., Storb, R. & Sullivan, K.M. (1996a) Barriers to bone marrow transplantation for sickle cell anemia. Biology of Blood and Marrow Transplant, 2, 100-104.
100. Walters, M.C., Patience, M., Leisenring, W., Eckman, J.R., Scott, J.P., Mentzer, W.C., Davies, S.C., Ohene-Frempong, K., Bernaudin, F., Matthews, D.C., Storb, R. & Sullivan, K.M. (1996b) Bone marrow transplantation for sickle cell disease. New England Journal of Medicine, 335, 369-376.
101. Walters, M.C., Sullivan, K.M,. Bernaudin, F., Souillet, G., Vannier, J.P., Johnson, F.L., Lenarsky, C., Powars, D., Bunin, N., Ohene-Frempong, K., Wall, D., Michel, G., Plouvier, E., Bodigoni, P., Lutz, P., Sanders, J.E., Matthews, D.C., Patience, M., Appelbaum, F.R. & Storb, R. (1995) Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood, 85, 879-884.
102. Wang, W.C., Kovnar, E.H., Tonkin, I.L., Murhern, R.K., Langston, J.W., Day, S.W., Schell, M.J. & Willmas, J.A. (1991) High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. Journal of Pediatrics, 118, 377-382.
103. Ware, R.E., Steinberg, M.H. & Kinney, T.R. (1995) Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. American Journal of Hematology, 50, 140.
104. Wayne, A.S., Kevy, S.V. & Nathan, D.G. (1993) Transfusion management of sickle cell disease. Blood, 81, 1109-1123.
105. Wethers, D.L. & Grover, R. (1987) Reversibility of splenic function by transfusion in two young adults with sickle cell anemia. American Journal of Pediatric Hematology and Oncology, 9, 209-211.
106. Wood, A. & Davies, S.C. (1995) Induction of hemoglobin F in sickle cell anemia by sodium valproate. (Abstract). Blood, 86, (Suppl. 1), 141a.
107. Zago, M.A., Costa, F.F., Freitas, T.C. & Bottura, C. (1980) Clinical, hematological and genetic features of sickle-cell anemia and sickle cell β-thalassemia in a Brazilian population. Clinical Genetics, 18, 58-64.
108. Ziegler-Skylakakis, K., Schwartz, L.R. & Andrae, U. (1985) Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutation Research, 152, 225-231.